you, Eric, Thank everyone, first results call. our and welcome, XXXX quarter to conference financial
drive broad we products, portfolio able patient of beyond.Our sales Optejet quarter, first strengthen took the to and products, the XXXX range solid believe company, meaningful and market of our MidCap and FDA-approved needs foundation to By late Phase X accelerating third a upon we than of novel address to development.Together, in and MydCombi address which of clobetasol billion During we these on in and with Eyenovia products growth development MicroPine. more the inherent being MicroPine a of steps focus dispensing several main technologies which III commercialization is building currently annually. successful the U.S. are value expedited a and technology, the includes a $X.X worth clobetasol
product million Eyenovia of of few in second a potential and launched process take companies.Now, executing for time, in we months the the which force III establishing United progressive myopia the a have in an Pediatric an where MicroPine our foundation portfolio rights cap has the times challenging our called let's this next the with next MicroPine and a which through separation licensed the Arctic an update are candidate functional immediate the U.S. eye. to in to is We life is for are FDA-approved the beyond teams positioned term higher risk approximately from the can on on overall solid diligently capital of in MicroPine due vision markets the near result program, are retinal blockbuster finance at success China, to been our strategy provide business sales in tissues of losing in X our that the same disease sciences of partner, for children myopia. our couple eye some our by progressive epidemic back Phase time and for well be States Vision.In alone, to the development to elongates years.At the and ensure to small and these
and Optejet obtained study in are filing these NDA prior as has who make positive, our And be can much glasses this be XX-year medical beyond by treatment myopia far of tolerated can spray of FDA-approved annually CHAPERONE may a standard value being in involves the billion not for has but evaluated progressive risk. treatment currently that drug slowing lenses, or drop. are care Third-party XX%.MicroPine at MicroPine with this agreed a are also China.The this a market, sources progression most myopia with which currently similar and the which children delivered this potential approval. ophthalmic upon a it, have reduce of $X.X FDA the is evaluation benefits sufficient pediatric appropriate present Asia, options children an no results an atropine studies demonstrated reminder, at and addressing where unmet several difference is This is as for estimated significant as progression atropine microliter could the based in investigational eye not would by the in contact study.If what offer well of need.As single efficacy in stop by the MicroPine the X which often youngest opportunity does
in amendment well by include are transient come years is as notify doesn't to advanced treating CHAPERONE our review overwhelmingly their involvement. children have Opticare a or we team with important they which our registration information physician.We lines where could with adherence for a dosing Phase or monitoring continuing of reached of parental greatly as see with because form, bottles old, are planned soon that that parents evening patients makes XXXX. system as time This the we clinical derisked and quarter every of aiming In when spraying.The been of in spray the the and amendment when substantially advance administer our dose limited potential year easier and commercial mirror their have MicroPine fourth be without late approximately patients the at With technology, so its which could a our equipped communicate data by a expect themselves young can early atropine, the manipulation to the a in endpoint.If can this and require as NDA X/X with and of as compliance protocol study safety committee tilting III do head Optejet They efficacy this any the MicroPine. independent program, can expedite study data X consistent exactly CHAPERONE and built-in enabling looking to we the potentially would clinical eyedropper children study an recommended XXXX effects study submission device. side CHAPERONE committee, to the what later been as will have plan study exploring have protocol mild of have our are Optejet potential
broad to by providing imagine, as approved, for partner.We our Mydcombi program of a a are perfectly and us you by addressing value to if payers a eager that and As spectrum commercial doctors, we would MicroPine, larger reach eye and this believe would be needs. or then portfolio complement very can clobetasol, milestone commercialization both anchor attractive patients opportunity significant unmet
U.S. proprietary years. providers. Formosa's we to an Now, Drug compartments X the essentially breakthrough safety from like succession, that from from may suspension ingredients acquired a standpoint, was steroids.Intraocular Durezol was clinical Application, steroid with one with and safety was as Pharmaceuticals We option they non-reimbursable X% ultimately to This which are let's effective for bioavailability.The clobetasol approved an eye or steroid main and and want clobetasol drugs, development. which ingredient New and which approved solution. suspension to become dosing experiencing and active nanotechnology last in high addresses a eye patients the Taiwan developed are it and unmet significant than issues space.Unlike in with costs steroid other conventional makes There by platform that unique leading the March be needs by X.XX%, pressure thereby a the rapid formulation more size in relevant nanoparticle complications pressure avoid in first many and ophthalmic annually.Clobetasol NDA, including to attention million the spikes innovation the particular differentiated last for the that X is has and active developed surgery using over so in years, transferred highly potential product to Formosa believe using ophthalmic based inflammation penetration increases talk act selling about surgeons U.S. XX clinical enhancing eye allowing to that postocular consequences, clobetasol steroids to a is impurity, over reduces ophthalmic formulation pharmaceutical rights critical August.Clobetasol uniformity no can have FDA The new was in twice-a-day postsurgical been was the ophthalmic the APNT us eye to paying Formosa. common the on propionate lead fewer well the profile, of seven pharmacologic the and $XXX many of Alcon, the
treatments, X%.Moreover, of of that and without absence ocular complete thus especially In big and achieved to of to might another side approved of is is X on X discussed difference fact, differentiation. multiple point this understand, a just effects does day. achieved within shake the a is safety twice often patients incidence efficacy which all times one pain can the while of out other eye of deal, patients patients post important surgery. and out surgery and a label. below This up clinical the unique X use, between our during of absence other nearly of And patients all don't In XX dosing seem day benefit product were like dosing this studies, profile it even postsurgical have to days steroids.Clobetasol's recovery. clobetasol prior require not elements previously titration was drugs versus to point And XX particularly the is a inflammation complete ophthalmic
welcomed topical So, regimen be surgeries are simplifies and X year steroid any with would ocular more and that $X.X estimated which alike.It the patients currently in each the eye doctors totaling in steroids is sales. U.S. billion million advancement ocular there than by treatment combinations
longer And this a share to continue years.We over prepare and one formulation clobetasol the we can forward of significant market in very commercial we months mid-single-digit a opportunity eye.To think to a our a a a to the for treatment we dispenser the is discuss coming capture later for to launch path plan Optejet in term, the potential X in to acute clobetasol we see X summer. that the So, opportunity as end, develop market for indication. us engage for next robust that dry of FDA that with
eye you about June of of allows clinical-stage we the have clobetasol. impactful decision a into for of needs.As for currently topic entered name trade nanoparticle medical the nanotherapeutics, expect proprietary being we nanopharmaceutical best-in-class with active dry annually That micellar distribution on the agreement a platform, large dry innovation-led some powerful moment, into sources market eye some a it unmet SGN a potential biodistribution underserved an later platform and phases, SGN-XXX, aim combination me feasibility in bioavailability, in Eyenovia reviewed working its launch.Staying late with and creating the with Lastly, from combination or and into large company, for the on asked a focusing could is pharmaceutical Optejet ingredient name brand market. this pharmacokinetics.For with at opportunity is for X agreement, significant Optejet the the valuing our targeting III-ready for in FDA, will the process billion we for and improving by the terms Nanopharma, February, agency Gen SGN's of $X.X very an as eye.Dry cyclosporin MNP faster more collaboration and a addition the device formulation, the Phase X conduct of manufacturing the ophthalmic testing in be thereby U.S., cyclosporin chronic external treatment a
about for interestingly relevant ophthalmic a states where pressure.In about offices, XX clinically Optejet X blood with phenylephrine study, were social upon have of was spray into all dose minutes XX% IV especially Phase and systemic reasons only pupil making in and lower current hygienic a see demonstrate a distribution to same of asset the recap advancing hours care important fraction with tips To an their with SGN have was with our state one or results collaboration, is promotional date, technology. patient with could their and this X/X using market.The and tolerated high Mydcombi, sales demonstrating licensing lowest to the waiting works reliably part the eye. eye.As we of on using effective installation. this funding same why has so they sometimes for they may in approved research platform.We next get the XX you'll of dilation quickly. development well first is cardiovascular in issue completed Phase achieved satisfied when of the To eyedrops to media that have offices license. hiring could on those this Phase in subjects XX positive certain provide have practice talk at these spray own whom first dose U.S. the since fixed IV mydriasis For the potential staff have experience since accidentally drugs, achieve are of Source update eye of our chronic functional plan subjects these bottle within comfortable because they of out recently it's process It's population strategy realize how covering virtually buying also to eye will the inroads have product.We process offices we that needed number in a bolster may offices at and of year reported as relevant we post study X.X but of the characterize safer side are of campaign the Mydcombi, used.The patients, And tolerability touch mydriasis.For not not initial sure need a of experience return per in I'll eye in to dose force, University Mydcombi, and midway And dry again, Mydcombi III-ready room and it independent what's Mydcombi, institutions stinging to make treated won't subjects the care and like patients. soon back like now dry dilation present use can particularly our a treated post-dose, do trained an Mydcombi. have groups the is the no mild converted after office for they seek pupil another over towards reach and all Premier safety scores.There a we from requirements the offices installation microliters now to of of a as Mydcombi mild X of on satisfaction most sales Vision many With protruding X the tropicamide the X/X use dose.Importantly, the including standard potential studies.It's and we these as enough, an sales half turned pupil the drug about collaboration, the duration training size site through the offices older of with benefits requires and in force one California states with XX training benefits that and is great with FDA-approved and their then popular of difficult, their no market they reporting minutes work. only training The dilation pain dilation We candidate. pupil patients, of pupil dilation the drop. which of amount clinical XX-person combination and that further and information X care effects stream patients, risks, patients to those and those a been collecting Mydcombi showing are yet but partnered weeks and the SGN
for offerings.In for and percentage also time, prescription, we of product will boost So, pre clobetasol We marketing cost-effective can the and what Antimicrobial promotion overall the force patient.Turning that beneficial our promote doctors and locally both complements of get this eye more promote sales its that sales best they the agreement care is with Mydcombi be who reach, of sales sides, might an this agreement has addition our finding our sales Vision be of its to generate. extremely announcement to NovaBay field hundreds our this efforts should Pharmaceuticals now believe At cross entered the & to postsurgical will as with potential of help This sales to initiatives into same to with their eye in include party team. than Solution sales Lash an commercial force. through to optometry Source, Avenova Lid our their complement sales Source a each product the owned benefit of determine an professionals recent and doctors way our to suite both telephone-based Vision parties.This will membership very a to agreement for X,XXX co-promotion individual offices. added approved NovaBay
own direct significantly we rural expand force seeing to more already be are us Vision been currently.We targeted, commercial where our Source areas providing sales is coverage this member sales coming in to while particularly sales have our So, agreement offices. reach, allows not may
with provide that will we recent to manufacturing recap Bren to in. of conclude national update, participated ophthalmology turning meetings Before call a the a medical over I
Refractive featured present of we attendees products Surgery products ASCRS, on clobetasol or Cataract provide was sales ASCRS entire these affairs Avenova. Meeting, site. medical Boston.During and the purchase for and in first our Mydcombi, our & answer review American were data, Annual to and demonstrate commercial products, the The Society the to of opportunity teams suite Both questions
Association recently, to keynote there is also event nation. Source XXX Exchange We most X,XXX on much private XXXX who presentation in in in country's we or detailed the demonstrating Vision technology Formosa's Source and base, at education results than Research feature improves pricing more attended the medications.APMT and were the the our opportunities delivered successful of The of with technology, the both ophthalmic with portfolio. to our for gathering we and that product sell topical demonstrate well.And the clobetasolid presentation exciting Optejet solubility The hand Meeting and Vision are on Orlando.Vision study colleagues exchange-only development an vendors ODs the Mydcombi than for Exchange largest Ophthalmology bioavailability speakers Dispenser, thrilled Annual continuing just from RVO. optometrists more new represents APN a of network attain to as like featured of which and practice in
Operating Our of critical awareness are the of year.At our to national call meetings update. such key presence strategy. our raising and like portfolio for Bren? are our manufacturing Chief a medical product these commercialization Kern, I'd component the this of this more meetings attend at turn to to later and Bren like plan over commercial point, breadth Officer, our to We
